Elizabeth Hassler, APRN
Gerontology · Reno, NVNPI 1295478303
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 78.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $4,556 and has fallen 87.1% since, to $590 in 2025. Among gerontology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $54.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Abbott$1K
- Actelion Pharmaceuticals US, Inc.$67
- Kiniksa Pharmaceuticals International, PLC$56
- Pfizer$56
- Johnson & Johnson$32
- plus $183 from 9 others
What the payments were for
- Travel & lodging$3,49347%
- Food & beverage$3,79051%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 109 | $5,841 |
| Abbott | 8 | $1,180 |
| Actelion Pharmaceuticals US, Inc. | 3 | $67 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $56 |
| Pfizer | 2 | $56 |
| Johnson & Johnson | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Merck | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,414 in reported general payments places this provider in the 90th percentile of 72 gerontology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 200 | $251,173 |
| XareltoRivaroxaban | 94 | $108,521 |
| FarxigaDapagliflozin Propanediol | 46 | $49,692 |
| Repatha SureclickEvolocumab | 40 | $38,671 |
| JardianceEmpagliflozin | 27 | $27,844 |
| EntrestoSacubitril/Valsartan | 19 | $19,628 |
| Atorvastatin Calcium | 293 | $5,457 |
| Rosuvastatin Calcium | 222 | $4,734 |
| Metoprolol Succinate | 255 | $4,216 |
| Carvedilol | 196 | $4,206 |
| Losartan Potassium | 175 | $2,213 |
| Ezetimibe | 54 | $1,694 |
| ClopidogrelClopidogrel Bisulfate | 70 | $1,664 |
| Potassium Chloride | 63 | $1,500 |
| Lisinopril | 147 | $1,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $251,173200 claims |
| Johnson & JohnsonXarelto | $32 | $108,52194 claims |
| AstraZenecaFarxiga | $14 | $49,69246 claims |
| Boehringer IngelheimJardiance | $18 | $27,84427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 72 gerontology providers in Nevada.
Other gerontology in Reno
- Jennifer GriffoReno$8K
- Preston PetersonReno$3K
- Marian GnandtReno$594
- Holly PorterReno$472
- Ann EganReno$453
- Rachel ChattinReno$382
- Marina VyshutinaReno$360
- Caleb FrinkReno$158
- Jennifer LanghamReno$148
- Deborah WalkerReno$122
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.